Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Obukhov

Showing results (301-310 of 303) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 303 results.
Nature Microbiology|November 25, 2021
Global phylogeny of Treponema pallidum lineages reveals recent expansion and spread of contemporary syphilisMathew A Beale, Michael Marks, Michelle J Cole, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2025
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674]Lev Demidov, Igor Samoylenko, Galina Kharkevich, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trialLev Demidov, Igor Samoylenko, Galina Kharkevich, et al.
Pageof 31

Showing results (301-310 of 303) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 303 results.
Nature Microbiology|November 25, 2021
Global phylogeny of Treponema pallidum lineages reveals recent expansion and spread of contemporary syphilisMathew A Beale, Michael Marks, Michelle J Cole, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2025
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674]Lev Demidov, Igor Samoylenko, Galina Kharkevich, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trialLev Demidov, Igor Samoylenko, Galina Kharkevich, et al.
Pageof 31